Cost-effectiveness watchdog NICE, often criticised for rejecting pricey new drugs, may actually be too generous in approving medicines for use in the National Health Service, experts said on Friday.
"The uncomfortable truth is that NICE's threshold has no basis in either theory or evidence," John Appleby, chief economist at the King's Fund think tank, and colleagues at City University in London wrote in the BMJ.
No comments:
Post a Comment